Uniphar Plc · EURONEXT:UPR
Uniphar — Shareholder Meeting (May 2020)
24 slides from Uniphar's shareholder meeting presentation, May 26, 2020
Slide 1: Trusted Global Partner – Annual General Meeting 2020
Trusted Global Partner Delivering to over 160 countries worldwide Annual General Meeting 2020 Ger Rabbette, CEO 26th May 2020
Slide 2: Disclaimer
Disclaimer This presentation (hereinafter “this document”) has been prepared by Uniphar plc (the “Company“) for information purposes only. This document has been prepared in good faith but the information contained in it has not been independently verified and does not purport to be comprehensive. T
Slide 3: Uniphar at a Glance
Divisional Gross Profit Overview Supply Chain & Retail 10% Commercial & Clinical Product Access 2019 Uniphar at a Glance 48% 42% €180.6m A diversified international healthcare service provider GP Supporting 200 multinational pharmaceutical and medical manufacturers across three divisions – 200 Comme
Slide 4: Highlights
Highlights Financial Highlights Strategic Initiatives Gross Profit: €180.6m, 7% organic growth IPO in July provides capital structure to execute growth plans EBITDA1: €48.0m (pre impact of IFRS 16) Durbin, M3 & EPS acquisitions complete and integration progressing in line with plan €58.6m (after imp
Slide 5: Financial Highlights
Financial Highlights uniphar.ie 5
Slide 6: Gross Profit
Gross Profit Diversified healthcare services business focused on growth markets 48% 2019 Organic 2019 GP 2018 GP Growth Growth €180.6m €’m €’m % % GP 10% Commercial & Clinical 76.8 35.4 117% 5% 42% Product Access 17.2 10.3 66% 16% Supply Chain & Retail 86.6 70.0 24% 8% 60% Total 180.6 115.7 56% 7% 2
Slide 7: 2020 Liquidity / Year-end Liquidity
Year-end Liquidity 2020 Liquidity Cash & Cash equivalents €116.2m Year End Position €’m Net Bank Cash at year end €26.6m Cash & Cash equivalents 116.2 Net Bank Debt / EBITDA Leverage Bank Borrowings (89.6) Year end position = 0x(1) 2020 Bank Covenant = 4.2x Net Bank Cash at year end 26.6 Uncommitted
Slide 8: Divisional Review
Divisional Review uniphar.ie 8
Slide 9: Commercial & Clinical
Sales, marketing and Building a pan-European service offering from the Commercial present footprint in Ireland, the UK, Benelux and distribution solutions for & Clinical the Nordics manufacturers Financials Revenue Gross Profit €204.0m €76.8m HCP interactions 2018 >340k Organic GP Growth 2019 >580k
Slide 10: Product Access
Providing access to Product Platform in place to become a global unlicensed and speciality leader in the provision of On Demand and medicines globally Access Exclusive Access services Financials Revenue Gross Profit Gross Profit €132.2m €17.2m 2018 Reported Organic Gross Profit Growth 2019 Uniphar (
Slide 11: Supply Chain & Retail
Market leader in Irish Supply Chain Leverage high-tech distribution facilities, wholesale and hospital longstanding manufacturer relationships and market. Supported by a & Retail scalable digital infrastructure network of 287 pharmacies(1) Financials Uniphar Volume Growth vs Market Volume Growth Rev
Slide 12: Strategic Initiatives
Strategic Initiatives uniphar.ie 12
Slide 13: Divisional Objectives
Divisional Objectives Supply Commercial Product Chain & Clinical Access & Retail Pan-European Market Market Share Platform Leadership Client Business Operational Growth Development Optimisation Digital Patient Retail Solutions Focused Excellence uniphar.ie 13
Slide 14: 2019 Acquisitions: Integration Update
2019 Acquisitions: Integration Update 3 Acquisitions completed in 2019 across ‘Growth Divisions’ Both acquisitions aligned with our strategy connected to therapeutic expertise Ireland, UK, Benelux, Nordics & Baltics EPS & M3 Strategic therapeutic expertise Add significant experience across Intervent
Slide 15: Sustainability and Governance
Sustainability and Governance Environmental We have a pro-active approach to managing our environmental obligations. Energy savings of 334 tonnes of Co2 in 2019 in our Citywest HQ, 16% savings on 2018. 96% recovery/recycling rate on all packaging Community Involvement Across each of our three divisi
Slide 16: COVID-19; Uniphar's role
COVID-19; Uniphar’s role Uniphar has taken measures to ensure continuation of Global platform vital services ➢ Consultation and strategic planning discussions with ▪ Patient Access services to over 160 Government & Regulators countries worldwide ➢ COVID Crisis Committee in place ▪ Running Global MAP
Slide 17: Outlook & Capital Allocation
Outlook & Capital Allocation uniphar.ie 17
Slide 18: Medium Term Outlook
Medium Term Outlook Divisional Guidance | Medium term organic growth in gross profit, by division: Commercial Supply Product Access & Clinical Chain Double Mid Single Low Single Digit Digit Digit In the medium term M&A expected to make a meaningful contribution to gross profit in addition to organic
Slide 19: Capital Allocation
Capital Allocation 10% Reinvest to support growth Continue to invest in infrastructure, digital platforms, strategic 42% Capex and talent to deliver organic growth in line with medium term guidance Reinvest to - Planned investment in SC&R facility in 2020 Growth support through M&A M&A growth Growth
Slide 20: Q&A
Q&A uniphar.ie 20
Slide 21: Contact Details
Contact Details Brian O’Shaughnessy Group Director of Corporate Development +353 (0)1 428 7777 investor.relations@Uniphar.ie Q4 PR Public Relations Adviser to Uniphar Iarla Mongey +353 (0)1 475 1444; or +353 (0)87 235 6461 uniphar.ie 21
Slide 22: Appendices
Appendices ON uniphar.ie 22
Slide 23: Investment Case
Compelling Investment Case Market Opportunity • Increasing requirements for speciality products • Continued growth in outsourcing Experienced by manufacturers Industry Team • Highly fragmented European market • Executive management, line Experienced Compelling Market management and specialty / techn
Slide 24: Shareholder returns; IPO to date
Shareholder returns; IPO to date Price Eur IPO 1.15 High 1.75 Low 0.98 25th May 2020 1.70 Source: live.euronext.com uniphar.ie 24